(Q53505725)

English

Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.

scientific article published in October 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

phase III clinical trial

0 references

phase II clinical trial

0 references

0 references

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Antonio Avallone

10

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

Giacomo Cartenì

11

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

author name string

P Comella

1

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

F De Vita

2

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

S Mancarella

3

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

L De Lucia

4

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

M Biglietto

5

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

R Casaretti

6

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

A Farris

7

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

G P Ianniello

8

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

V Lorusso

9

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

S S Leo

12

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

G Catalano

13

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

M De Lena

14

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

G Comella

15

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

publication date

1 October 2000

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

11

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

10

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

1323-1333

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

Chemotherapy of Gastrointestinal Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The Nordic Gastroint

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: potentiating or reversing effect?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Concurrent modulation of 5-fluorouracil with methotrexate and L-leucovorin: an effective and moderately toxic regimen for the treatment of advanced colorectal carcinoma. A multicenter phase II study of the Southern Italy Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

The calculation of received dose intensity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

A two-stage design for choosing among several experimental treatments and a control in clinical trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Some Methods for Strengthening the Common χ 2 Tests

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008375705484

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008375705484

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/11106123

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53505725&oldid=1584689774"